Guess BW, Scholz MC, Strum SB, Lam RY, Johnson HJ, Jennrich RI. Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study. Prostate Cancer Prostatic Dis. 2003;6(4):301–4. DOI: 10.1038/sj.pcan.4500679. PMID: 14663471. I. Eliaz, et al., “The Effect of Modified Citrus Pectin on Urinary Excretion of Toxic Elements,” Phytother. Res. 20(10), 859–864 (2006).

MCP may also help to improve the permeability of the gut wall (“leaky gut”). In one randomized clinical trial, 57 male infants with diarrhea were fed either pectin, a green banana, or a rice diet. P.P. Ruvolo, “Galectin-3 as a Guardian of the Tumor Microenvironment,” Biochim. Biophys. Acta. 1863(3), 427–437 (2016). B.W. Guess, et al., “Modified Citrus Pectin (MCP) Increases the Prostate-Specific Antigen Doubling Time in Men with Prostate Cancer: A Phase II Pilot Study,” Prostate Cancer Prostatic Dis. 6(4), 301–304 (2003).Another study suggested that MCP made it difficult for metastatic cancer cells to join together and grow in other parts of the body. In a small human study with prostate cancer, those taking MCP showed slower growth of PSA levels (2) . In this pilot study, 15 grams of MCP (this study used PectaSol by EcoNugenics Inc.) taken orally did not increase the loss of calcium, magnesium, zinc, selenium or iron. But it did decrease toxic arsenic, cadmium, and lead levels [ 3]. Induced inhibition of proliferation, accumulation of cells in sub-G1 and G1 phases, and apoptosis with activation of both caspase-8,

Nutritional Supplements by Nutricentral.co.uk - information and products are not intended to diagnose, treat, cure, or prevent any disease Of all 49 patients, 22.5% had stabilized cancer and 12.3% were stable for longer than six months. One patient with metastasized prostate cancer had 50% fewer prostate-specific antigen (PSA) in his system after 16 weeks on modified citrus pectin. PSA levels may indicate the likelihood of prostate cancer progression [ 8]. Additional inflammatory conditions, including liver and kidney disease, arthritis, obesity, neurodegeneration and infection have all shown a significant reduction by this researched form of MCP. Another randomized control trial concluded that at least 6 grams a day of pectin benefited cholesterol levels [ 6]. This trial also showed that citrus pectin was more effective than pectin derived from apples.

N. Tehranian, et al., “Combination Effect of PectaSol and Doxorubicin on Viability, Cell Cycle Arrest and Ppoptosis in DU-145 and LNCaP Prostate Cancer Cell Lines,” Cell Biol. Int. 36(7), 601–610 (2012). Today, Gal-3 heralds one of the fastest growing fields of medical research, with compelling new data and large-scale studies continuing to highlight the mechanisms by which the overexpression of Gal-3 acts as an upstream initiator for an exhaustive range of pathogenic processes. As the research on this form of MCP continues, it’s critical to note that, in the nutraceutical world, MCP is not a carefully defined term. Experts emphasise that other “modified” citrus pectins do not offer the same benefits as the only researched, clinically studied and substantiated MCP. Circulating Gal-3 is often substantially elevated in patients with cancer, particularly metastatic cancer. Because of its primary roles in cancer formation and progression, Gal-3 has been termed “the guardian of the tumour microenvironment.” 6 MCP may also help with the activation of natural killer cells, as well as T-cytotoxic cells, helping the immune system to fight leukemia [ 11].

Natural pectin is something that we’re all familiar with, even if we don’t know what it’s called. This is the spongy pulp found in the peels of citrus fruits such as oranges, limes, lemons, and grapefruit, as well as in apples and plums. Suppressed the viability in MDA-MB-231, MCF-7 and T47D human Breast cancer cells, ↓ mRNA expression of galectin-3 Since the eligible patients have no other evidence of active disease at the time of enrollment, according to previously reported clinical trials in such patients [ 4, 14], we relied on PSA dynamics changes as a potential signal for antitumor activity. Based on prior data, any expression of PSA dynamics (e.g., PSADT, PSA slopes) represents the strongest prognosticator in this population [ 4, 11]. Although the number is small, and no definitive conclusions can be drawn, in all three patients with on-treatment radiological disease progression in the present study, on treatment PSA progression and no lengthening of PSADT were observed (in accordance with data suggesting that the endpoints of PSA dynamics and PSADT are in correlation with disease control).As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, Xu L, Yu W, Jiang J, Feng X, Li N. [Efficacy of pectin in the treatment of diarrhea predominant irritable bowel syndrome]. Zhonghua Wei Chang Wai Ke Za Zhi. 2015 Mar;18(3):267–71. PMID: 25809332. Modified citrus pectin (MCP), a type of supplemental dietary fiber (a polysaccharide) made from the pulp of citrus fruits, offers a wide range of possible benefits from slowing or preventing heart disease and cancer growth to healing the gut wall and improving cognition. Eligible patients were ≥21 years old and had histologically proven prostatic adenocarcinoma. All participants had undergone radical prostatectomy and/or external beam radiation therapy, or brachytherapy, with, subsequently, a confirmed rising serum PSA level (in at least three consecutive tests, at least two weeks apart) of ≥0.2 ng/mL after radical prostatectomy or ≥2 ng/mL above nadir after radiation therapy. Patients’ participation required no evidence of locoregional or distant metastasis determined by a positron emission tomography (PET) prostate-specific membrane antigen (PSMA) scan. All previous local treatment modalities, including radiation and surgery, were completed at least three months before treatment in this study. Patients with prior systemic treatment with androgen deprivation therapy (ADT), experimental drugs, high-dose steroids, or other cancer treatments were discontinued at least six months before study admission. All patients had a normal level of serum testosterone > 150 ng/mL, and adequate bone marrow (absolute neutrophil count ≥ 1.5 × 10 3/L, platelet count ≥ 100 × 10 3/L), renal (creatinine ≤ 2.5 times the normal upper serum limit), and liver (total bilirubin ≤ 1.5 mg/dL, aspartate aminotransferase (AST) and alanine transaminase (ALT) ≤ 2 × upper limit of normal range) functions. In addition, all patients had an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2, a life expectancy > 6 months at study entry. Men were excluded if they had an uncontrolled intercurrent illness that limited study compliance. All participating patients signed an institutional review board (IRB)-approved consent form. Clinical Registry; {"type":"clinical-trial","attrs":{"text":"NCT01681823","term_id":"NCT01681823"}}NCT01681823; https://clinicaltrials.gov/ct2/show/ {"type":"clinical-trial","attrs":{"text":"NCT01681823","term_id":"NCT01681823"}}NCT01681823, accessed on 22 November 2021. Cancer cell proliferation, migration and colony formation, induced pancreatic cancer cells apoptosis, suppressed autophagy